Dry Eye:
I was the person who originally conceived the use of cationic emulsions for the treatment of dry eye conditions.
The initial report on the merits of cyclosporine cationic emulsion was my very first ARVO abstract submission:
Abdulrazik et al.; Effect of emulsion droplet surface charge on cyclosporine ocular tissue distribution; IOVS; vol. 42, No. 4, Mar. 15, 2001; p. S925.
The project went on to produce the first EPA-approved topical formulation of cyclosporine for the treatment of dry eye (IKERVIS).
Biopharmaceuticals:
In recognition of the growing role of biopharmaceuticals in modern medicine, the focus of my research efforts in recent years has shifted toward understanding the obstacles that prevent biopharmaceuticals from continuing to expand the frontiers of curative pharmaceutical interventions.
Related ARVO presentations:
Biopharmaceuticals: are you into designing your own one? then here’s the most decorated build recipe – based on architectures with most wins in 2015-2021 FDA’s Novel Drug Approvals
Physics is the law, the rest is about consequences: Novel physicochemical Insights on how safety/efficacy balance of recently approved ocular anti–VEGFs is being pushed to the edge